| Literature DB >> 23418506 |
Christiane P Goulart1, Mentar Mahmudi, Kristina A Crona, Stephen D Jacobs, Marcelo Kallmann, Barry G Hall, Devin C Greene, Miriam Barlow.
Abstract
The evolution of antibiotic resistance among bacteria threatens our continued ability to treat infectious diseases. The need for sustainable strategies to cure bacterial infections has never been greater. So far, all attempts to restore susceptibility after resistance has arisen have been unsuccessful, including restrictions on prescribing [1] and antibiotic cycling [2], [3]. Part of the problem may be that those efforts have implemented different classes of unrelated antibiotics, and relied on removal of resistance by random loss of resistance genes from bacterial populations (drift). Here, we show that alternating structurally similar antibiotics can restore susceptibility to antibiotics after resistance has evolved. We found that the resistance phenotypes conferred by variant alleles of the resistance gene encoding the TEM β-lactamase (bla(TEM)) varied greatly among 15 different β-lactam antibiotics. We captured those differences by characterizing complete adaptive landscapes for the resistance alleles bla(TEM-50) and bla(TEM-85), each of which differs from its ancestor bla(TEM-1) by four mutations. We identified pathways through those landscapes where selection for increased resistance moved in a repeating cycle among a limited set of alleles as antibiotics were alternated. Our results showed that susceptibility to antibiotics can be sustainably renewed by cycling structurally similar antibiotics. We anticipate that these results may provide a conceptual framework for managing antibiotic resistance. This approach may also guide sustainable cycling of the drugs used to treat malaria and HIV.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23418506 PMCID: PMC3572165 DOI: 10.1371/journal.pone.0056040
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Constructs containing all possible combinations of the four mutations found in bla TEM-50 and bla TEM-85.
| Number of Substitutions | Binary Allele Code | Variants with mutations found in | Variants of mutations found in |
| 0 | 0000 | No Mutations | No Mutations |
| TEM-1 | TEM-1 | ||
| 1 | 1000 | M69L | L21F |
| (TEM-33) | (TEM-117) | ||
| 1 | 0100 | E104K | R164S |
| (TEM-17) | (TEM-12) | ||
| 1 | 0010 | G238S | E240K |
| (TEM-19) | (Not identified) | ||
| 1 | 0001 | N276D | T265M |
| (TEM-84) | (Not identified) | ||
| 2 | 1100 | M69L | L21F |
| E104K | R164S | ||
| (Not identified) | (TEM-53) | ||
| 2 | 1010 | M69L | L21F |
| G238S | E240K | ||
| (Not identified) | (Not identified) | ||
| 2 | 1001 | M69L | L21F |
| N276D | T265M | ||
| (TEM-35) | (TEM-110) | ||
| 2 | 0110 | E104K | R164S |
| G238S | E240K | ||
| (TEM-15) | (TEM-10) | ||
| 2 | 0101 | E104K | R164S |
| N276D | T265M | ||
| (Not identified) | (Not identified) | ||
| 2 | 0011 | G238S | E240K |
| N276D | T265M | ||
| (Not identified) | (Not identified) | ||
| 3 | 1110 | M69L | L21F |
| E104K | R164S | ||
| G238S | E240K | ||
| (Not identified) | (TEM-102) | ||
| 3 | 1101 | M69L | L21F |
| E104K | R164S | ||
| N276D | T265M | ||
| (Not Identified) | (Not identified) | ||
| 3 | 1011 | M69L | L21F |
| G238S | E240K | ||
| N276D | T265M | ||
| (Not identified) | (Not identified) | ||
| 3 | 0111 | E104K | R164S |
| G238S | E240K | ||
| N276D | T265M | ||
| (Not identified) | (Not identified) | ||
| 4 | 1111 | M69L | L21F |
| E104K | R164S | ||
| G238S | E240K | ||
| N276D | T265M | ||
| (TEM-50) | (Not identified) |
The antibiotics used to characterize adaptive landscapes.
| Antibiotic | FDA approval | Antibiotic Group |
| Ampicillin (AM) | 1963 | Penicillin derivative |
| Cefoxin(FOX) | 1978 | Cephalosporin |
| Cefaclor(CEC) | 1979 | Cephalosporin |
| Cefotaxime (CTX) | 1981 | Cephalosporin |
| Ceftizoxime (ZOX) | 1983 | Cephalosporin |
| Cefuroxime (CXM) | 1983 | Cephalosporin |
| Ceftriaxone(CRO) | 1984 | Cephalosporin |
| Amoxicillin +Clavulanic acid (AMC) | 1984 | Penicillin derivative+β-Lactamase inhibitor |
| Ceftazidime (CAZ) | 1985 | Cephalosporin |
| Cefotetan (CTT) | 1985 | Cephalosporin |
| Ampicillin+Sulbactam (SAM) | 1986 | Penicillin derivative+β-Lactamase inhibitor |
| Cefprozil (CPR) | 1991 | Cephalosporin |
| Cefpodoxime (CPD) | 1992 | Cephalosporin |
| Pipercillin+Tazobactam (TZP) | 1993 | Penicillin derivative+β-Lactamase inhibitor |
| Cefepime(FEP) | 1996 | Cephalosporin |
While not a comprehensive listing of all β-lactam antibiotics, this set contains many heavily used antibiotics and provides good general coverage of β-lactams.
Figure 1Adaptive landscapes of TEM-85.
These diagrams show the pathways through which the bla TEM-85 can evolve in a single antibiotic. 1a. (Left) The TEM-85 adaptive landscape in cefotaxime with pathways to TEM-85 indicated. 1b. (Right) The TEM-85 adaptive landscape in ceftazidime with pathways to TEM-85 indicated.
Figure 2Example of one possible outcome from antibiotic cycling.
These diagrams show that by alternating the antibiotics cefepime, ceftazidime, and cefprozil susceptibility to those antibiotics can be restored in bacterial populations expressing variant alleles present in TEM-50 adaptive landscapes. 2a. (Top left) The TEM-50 adaptive landscape in cefepime. Yellow peaks indicate the adjacent alleles that are important during cefepime selection. 2b. (Top right) The TEM-50 adaptive landscape in ceftazidime. Orange peaks indicate the adjacent alleles that are important during ceftazidime selection. 2c. (Bottom left) The TEM-50 adaptive landscape in cefprozil. Red peaks indicate the adjacent alleles that are important during cefprozil selection. 2d. (Bottom right) Composite cycle: The yellow arrow indicates the direction of selection in the presence of cefepime. The red arrows indicate the direction of selection in the presence of cefprozil. The orange arrow indicates the direction of selection in the presence of ceftazidime. Rotation of these antibiotics results in cyclical renewal of antibiotic susceptibility.